🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "significant breakthrough" in the effort against superbug strains of the pathogen, according to researchers.

A Worldwide Challenge

Cases of gonorrhoea are on the rise worldwide, with data suggesting in excess of 82 million new cases each year. Particularly high rates are reported in Africa and countries within the WHO's designated area, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a all-time high, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune step in the face of growing infection rates, increasing antimicrobial resistance and the very limited available drugs currently available.”

Medical experts are deeply concerned about the increase in drug-resistant strains. The global health body has listed it as a "high-priority threat". Ongoing monitoring found that resistance to primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Drugs Secure Authorization

One new antibiotic, also known as Nuzolvence, was authorized by the US FDA in mid-December for treating gonorrhoea. This STI can lead to significant complications, including infertility. Researchers anticipate that focused deployment of this new drug will help hinder the spread of drug resistance.

Gepotidacin, created by the drugmaker GSK, was also approved in close succession. This drug, which is also used to treat urinary tract infections, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin stemmed from a new, not-for-profit approach for drug creation. The charitable organization GARDP collaborated with the pharmaceutical company its industry partner to see it through.

“This authorization marks a huge turning point in the treatment of superbug gonorrhoea, which up to this point has been outpacing antibiotic development.”

Clinical Trial Outcomes and Worldwide Availability

Based on findings published in a prominent scientific publication, the new drug successfully treated more than 90% of genital gonorrhoea infections. This puts it on an similar efficacy with the current standard treatment, which combines a dual-drug approach. The research enrolled over 900 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the authority to license and sell the drug in many low-income and middle-income countries.

Medical professionals on the front lines have voiced positive views. Having a one-pill regimen such as this is described as a "critical tool" for gonorrhoea control. This is considered vital to lessen the impact of the disease for individuals and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.